CARLSBAD, Calif., Oct. 8, 2012 /PRNewswire/ -- Life Technologies (NASDAQ: LIFE) today announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR and proteome analysis. Compendia's existing business, which will continue under the leadership of its current management team, adds an established base of pharmaceutical industry customers for Life Technologies' platforms. Compendia's oncology data is widely utilized by leading pharmaceutical companies in their drug development work and will extend Life's abilities to both develop its own tests and to partner with pharmaceutical companies in companion diagnostic development. "We have created the optimal foundation to drive progress in personalized medicine," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "By combining the acquisitions of Pinpoint Genomics, Navigenics and Compendia, we now possess the full spectrum capability to develop and commercialize high-value cancer diagnostics where there is currently great unmet need." The recent launch of Pervenio™ Lung RS, a first-of-its-kind prognostic test, underscores Life Technologies' strategy to focus initially on lung cancer, a highly underserved disease. The company plans to utilize the extensive content in Compendia to springboard to other areas of oncology. Preeminent Assets Widely Used by Leading Pharmaceutical Companies Compendia holds one of the world's largest and most comprehensive sets of mutation profiles, gene expression data and cellular biomarkers that have been gathered from more than 62,000 cancer patients. Oncomine™, the company's cloud-based analytics tool, integrates high-throughput cancer profiling data across a large volume of cancer types to allow users to mine it for correlations among genetic signatures, clinical status, and drug response markers. The proprietary technology is especially useful to Compendia's well-established pharmaceutical customer base. They use it to ascertain the genes most frequently mutated across thousands of samples of a given cancer type, as well as the biomarkers associated with biological responses to specific classes of compounds. Equally valuable is Compendia's OncoScore™ product, a tool that helps optimize the clinical trials process by stratifying patients based on genetic signatures so that individuals most likely to respond to specific drugs are included.